Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Medicenna Therapeutics Corp (MDNAF)

Medicenna Therapeutics Corp (MDNAF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Medicenna to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) GlobeNewswire - Fri Oct 4, 8:07AM CDT

MDNAF : 1.7800 (+3.46%)
MDNA.TO : 2.47 (+2.49%)
Medicenna to Present at the Bloom Burton & Co. Healthcare Investor Conference Globe NewsWire - Wed Apr 14, 2021

TORONTO and HOUSTON, April 14, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...

MDNAF : 1.7800 (+3.46%)
MDNA.TO : 2.47 (+2.49%)
MDNA : 0.1570 (-13.16%)
Medicenna Presents Preclinical Data Demonstrating Potent Immune Modulating Effects of an IL-2/IL-13 Dual Specific Cytokine at the 2021 AACR Annual Meeting Globe NewsWire - Mon Apr 12, 2021

-- The IL-2/IL-13 dual specific cytokine selectively stimulates anti-cancer immune cells and inhibits M2a polarization of pro-tumoral macrophages

MDNAF : 1.7800 (+3.46%)
MDNA.TO : 2.47 (+2.49%)
MDNA : 0.1570 (-13.16%)
Medicenna Announces Preclinical Data on MDNA11 with Anti-PD-1 Therapy and Unveils Novel Bifunctional Superkines at the Cytokine-Based Cancer Immunotherapies Summit Globe NewsWire - Thu Mar 25, 2021

-- MDNA11 and anti-PD-1 combination leads to complete responses in a murine solid tumor model

MDNAF : 1.7800 (+3.46%)
MDNA.TO : 2.47 (+2.49%)
MDNA : 0.1570 (-13.16%)
Medicenna Therapeutics Announces Upcoming Presentation at the AACR Annual Meeting 2021 Globe NewsWire - Thu Mar 11, 2021

TORONTO and HOUSTON, March 11, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...

MDNAF : 1.7800 (+3.46%)
MDNA.TO : 2.47 (+2.49%)
MDNA : 0.1570 (-13.16%)
Medicenna Therapeutics to Present at Upcoming March Investor Conferences Globe NewsWire - Thu Mar 4, 2021

TORONTO and HOUSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...

MDNAF : 1.7800 (+3.46%)
MDNA.TO : 2.47 (+2.49%)
MDNA : 0.1570 (-13.16%)
Medicenna to Present at the Cowen 41st Annual Healthcare Conference Globe NewsWire - Mon Feb 22, 2021

TORONTO and HOUSTON, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...

MDNAF : 1.7800 (+3.46%)
MDNA.TO : 2.47 (+2.49%)
MDNA : 0.1570 (-13.16%)
Medicenna to Present at the 10th Annual SVB Leerink Global Healthcare Conference Globe NewsWire - Wed Feb 17, 2021

TORONTO and HOUSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...

MDNAF : 1.7800 (+3.46%)
MDNA.TO : 2.47 (+2.49%)
MDNA : 0.1570 (-13.16%)
Medicenna Reports Third Quarter Fiscal 2021 Financial Results and Operational Highlights Globe NewsWire - Fri Feb 12, 2021

TORONTO and HOUSTON, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “Company") (NASDAQ: MDNA, TSX: MDNA), a clinical stage immuno-oncology company, today announced its...

MDNAF : 1.7800 (+3.46%)
MDNA.TO : 2.47 (+2.49%)
MDNA : 0.1570 (-13.16%)
Medicenna Establishes At-the-Market Sales Facility Globe NewsWire - Wed Dec 30, 2020

TORONTO and HOUSTON, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA, TSX: MDNA), a clinical stage immuno-oncology company, announced...

MDNAF : 1.7800 (+3.46%)
MDNA.TO : 2.47 (+2.49%)
MDNA : 0.1570 (-13.16%)

Barchart Exclusives

Up 160% in 3 Months, Is It Too Late to Buy Astera Labs Stock? Barchart - 17 minutes ago
Breakout semiconductor stock ALAB has more than doubled in just a few months. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot